B. Riley Issues Optimistic Outlook for Cytokinetics Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at B. Riley increased their FY2025 EPS estimates for shares of Cytokinetics in a research note issued on Monday, November 10th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings per share of ($5.63) for the year, up from their previous forecast of ($5.72). B. Riley currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.60) EPS, FY2026 earnings at ($6.47) EPS, FY2027 earnings at ($5.81) EPS, FY2028 earnings at ($3.52) EPS and FY2029 earnings at $0.41 EPS.

A number of other brokerages have also weighed in on CYTK. Royal Bank Of Canada upped their target price on Cytokinetics from $82.00 to $87.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen downgraded Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday. Barclays lifted their target price on Cytokinetics from $71.00 to $82.00 and gave the company an “overweight” rating in a research report on Monday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a report on Tuesday, September 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a report on Tuesday, October 21st. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average target price of $77.86.

Cytokinetics Price Performance

CYTK stock opened at $66.50 on Wednesday. The company’s 50-day moving average is $56.14 and its 200-day moving average is $42.47. The stock has a market capitalization of $8.13 billion, a PE ratio of -13.04 and a beta of 0.58. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $66.72.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. During the same period in the prior year, the company earned ($1.36) earnings per share. The firm’s revenue was up 318.1% compared to the same quarter last year.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $49.77, for a total value of $248,850.00. Following the completion of the transaction, the chief executive officer owned 373,108 shares in the company, valued at $18,569,585.16. This trade represents a 1.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 6,757 shares of Cytokinetics stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $60.00, for a total value of $405,420.00. Following the transaction, the director directly owned 9,778 shares of the company’s stock, valued at $586,680. The trade was a 40.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,983 shares of company stock valued at $3,165,356 over the last 90 days. 2.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cytokinetics

Hedge funds have recently bought and sold shares of the company. Thornburg Investment Management Inc. boosted its holdings in Cytokinetics by 16.2% in the 3rd quarter. Thornburg Investment Management Inc. now owns 84,719 shares of the biopharmaceutical company’s stock valued at $4,656,000 after purchasing an additional 11,840 shares during the period. US Bancorp DE lifted its position in Cytokinetics by 149.9% during the third quarter. US Bancorp DE now owns 4,308 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,584 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Cytokinetics by 23.4% in the 3rd quarter. TD Asset Management Inc now owns 671,780 shares of the biopharmaceutical company’s stock worth $36,921,000 after buying an additional 127,488 shares during the last quarter. Dana Investment Advisors Inc. grew its position in Cytokinetics by 4.9% in the third quarter. Dana Investment Advisors Inc. now owns 17,413 shares of the biopharmaceutical company’s stock worth $957,000 after acquiring an additional 811 shares in the last quarter. Finally, Intrust Bank NA purchased a new stake in Cytokinetics during the third quarter valued at about $250,000.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.